Recombinant Human Fas/CD95 Protein(HEK293)

Fas, also known as CD95, is a crucial cell-surface receptor that plays a significant role in the regulation of apoptosis, or programmed cell death. It belongs to the tumor necrosis factor receptor (TNFR) superfamily and primarily mediates the extrinsic apoptosis pathway. The interaction of Fas with its ligand, FasL, initiates a cascade of events leading to the activation of caspases, which are essential for executing the apoptotic program. This mechanism is vital for maintaining immune homeostasis, eliminating damaged or harmful cells, and preventing autoimmune diseases. Dysregulation of the Fas/CD95 pathway has been associated with various pathological conditions, including cancer, where tumor cells often evade apoptosis, allowing for uncontrolled proliferation. Additionally, insufficient Fas signaling can lead to autoimmune disorders due to the accumulation of autoreactive lymphocytes. In this context, the study of Fas/CD95 recombinant proteins has gained significant attention, as they can serve as valuable tools for understanding the intricate mechanisms of apoptosis and its implications in health and disease. Researchers are particularly interested in developing therapeutic strategies that manipulate the Fas pathway, either by enhancing its function to induce apoptosis in cancer cells or by inhibiting excessive apoptosis in autoimmune conditions. Moreover, recombinant Fas/CD95 proteins can be used in assays to study receptor-ligand interactions, signaling pathways, and the effects of small molecules or antibodies, paving the way for the development of targeted therapies. Overall, the research on Fas/CD95 recombinant proteins holds promise for advancing our understanding of apoptosis and its diverse roles in immunology and oncology.